{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PLacebo&page=35",
    "query": {
      "intervention": "PLacebo",
      "page": 35
    },
    "page_size": 10
  },
  "pagination": {
    "page": 35,
    "page_size": 10,
    "total_count": 33205,
    "total_pages": 3321,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PLacebo&page=36&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PLacebo&page=34&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T04:16:54.576Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01433055",
      "title": "Adjunctive Minocycline in Clozapine Treated Schizophrenia Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "Minocycline",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Maryland, Baltimore",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 52,
      "start_date": "2011-07",
      "completion_date": "2014-01",
      "has_results": true,
      "last_update_posted_date": "2019-08-28",
      "last_synced_at": "2026-11-19T04:16:54.576Z",
      "location_count": 1,
      "location_summary": "Catonsville, Maryland",
      "locations": [
        {
          "city": "Catonsville",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01433055"
    },
    {
      "nct_id": "NCT01756885",
      "title": "Extended Varenicline Treatment for Smoking Among Cancer Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Nicotine Dependence"
      ],
      "interventions": [
        {
          "name": "Varenicline",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Smoking Cessation Counseling",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 207,
      "start_date": "2013-01",
      "completion_date": "2018-05-31",
      "has_results": true,
      "last_update_posted_date": "2019-07-30",
      "last_synced_at": "2026-11-19T04:16:54.576Z",
      "location_count": 2,
      "location_summary": "Chicago, Illinois • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01756885"
    },
    {
      "nct_id": "NCT00131885",
      "title": "Effects of St. John's Wort on the Oral Contraceptive Hormone Levonorgestrel",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Contraception"
      ],
      "interventions": [
        {
          "name": "Placebo Control (Placebo Herb)",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "St. John's Wort",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Levonorgestrel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "DRUG"
      ],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "30 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 30 Years · Female only"
      },
      "enrollment_count": 36,
      "start_date": "2005-08",
      "completion_date": "2008-05",
      "has_results": true,
      "last_update_posted_date": "2023-11-13",
      "last_synced_at": "2026-11-19T04:16:54.576Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00131885"
    },
    {
      "nct_id": "NCT06825143",
      "title": "Therapeutic Strategies to Reduce Endothelial Ischemia-reperfusion Injury",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Metabolic Syndrome",
        "Vascular Injury",
        "Ischemic Preconditioning",
        "Endothelial Function (reactive Hyperemia)",
        "Endothelial Dysfunction"
      ],
      "interventions": [
        {
          "name": "Ischemic preconditioning",
          "type": "PROCEDURE"
        },
        {
          "name": "Intravenous lactate infusion",
          "type": "DRUG"
        },
        {
          "name": "No ischemic preconditioning (control)",
          "type": "PROCEDURE"
        },
        {
          "name": "Normal Saline Infusion (Placebo)",
          "type": "DRUG"
        },
        {
          "name": "Ischemic preconditioning and intravenous lactate",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Gary Van Guilder",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 68,
      "start_date": "2026-10-01",
      "completion_date": "2030-06-30",
      "has_results": false,
      "last_update_posted_date": "2025-02-13",
      "last_synced_at": "2026-11-19T04:16:54.576Z",
      "location_count": 1,
      "location_summary": "Gunnison, Colorado",
      "locations": [
        {
          "city": "Gunnison",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06825143"
    },
    {
      "nct_id": "NCT00105508",
      "title": "Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Parkinson's Disease",
        "Dyskinesia"
      ],
      "interventions": [
        {
          "name": "Sarizotan",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "EMD Serono",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "30 Years and older"
      },
      "enrollment_count": 506,
      "start_date": "2004-09-30",
      "completion_date": "2006-02-28",
      "has_results": true,
      "last_update_posted_date": "2018-07-26",
      "last_synced_at": "2026-11-19T04:16:54.576Z",
      "location_count": 31,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • La Jolla, California + 26 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Oxnard",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00105508"
    },
    {
      "nct_id": "NCT06960317",
      "title": "Empathy Through Pain Control: Lidocaine Paracervical Block for IUD Placements",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Contraception",
        "Pain, Acute",
        "Anesthesia, Local"
      ],
      "interventions": [
        {
          "name": "Buffered Lidocaine",
          "type": "DRUG"
        },
        {
          "name": "Sham Comparator",
          "type": "OTHER"
        },
        {
          "name": "Unbuffered lidocaine",
          "type": "DRUG"
        },
        {
          "name": "Xylocaine jelly 2%",
          "type": "DRUG"
        },
        {
          "name": "Surgilube",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of California, San Diego",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 50 Years · Female only"
      },
      "enrollment_count": 204,
      "start_date": "2025-06-04",
      "completion_date": "2028-06-30",
      "has_results": false,
      "last_update_posted_date": "2025-06-13",
      "last_synced_at": "2026-11-19T04:16:54.576Z",
      "location_count": 1,
      "location_summary": "La Jolla, California",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06960317"
    },
    {
      "nct_id": "NCT00995540",
      "title": "Tolerability, Safety, and Efficacy Study of INGAP Peptide to Treat Type 1 Diabetes Mellitus in Adults",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Type 1 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "INGAP Peptide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Exsulin Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "19 Years to 60 Years"
      },
      "enrollment_count": 23,
      "start_date": "2009-11",
      "completion_date": "2011-12",
      "has_results": false,
      "last_update_posted_date": "2014-02-12",
      "last_synced_at": "2026-11-19T04:16:54.576Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00995540"
    },
    {
      "nct_id": "NCT06039189",
      "title": "Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Moderate Plaque Psoriasis"
      ],
      "interventions": [
        {
          "name": "Guselkumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 338,
      "start_date": "2023-08-24",
      "completion_date": "2025-04-14",
      "has_results": true,
      "last_update_posted_date": "2026-05-01",
      "last_synced_at": "2026-11-19T04:16:54.576Z",
      "location_count": 45,
      "location_summary": "Birmingham, Alabama • Encinitas, California • Fountain Valley, California + 34 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Riverside",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06039189"
    },
    {
      "nct_id": "NCT00679432",
      "title": "(CB-01-02/01) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX™) 6 mg and 9 mg in Patients With Ulcerative Colitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Ulcerative Colitis"
      ],
      "interventions": [
        {
          "name": "Blood sampling, endoscopy",
          "type": "PROCEDURE"
        },
        {
          "name": "budesonide-MMX® 6 mg",
          "type": "DRUG"
        },
        {
          "name": "budesonide-MMX® 9 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Asacol® 400 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Bausch Health Americas, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 510,
      "start_date": "2008-06",
      "completion_date": "2010-06",
      "has_results": true,
      "last_update_posted_date": "2019-12-10",
      "last_synced_at": "2026-11-19T04:16:54.576Z",
      "location_count": 76,
      "location_summary": "Huntsville, Alabama • Mobile, Alabama • Sylacauga, Alabama + 67 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Sylacauga",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00679432"
    },
    {
      "nct_id": "NCT01027598",
      "title": "Randomized, Double-Blind Trial of Erlotinib/Pazopanib or Erlotinib/Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Pazopanib",
          "type": "DRUG"
        },
        {
          "name": "Erlotinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SCRI Development Innovations, LLC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 202,
      "start_date": "2010-01",
      "completion_date": "2014-06",
      "has_results": true,
      "last_update_posted_date": "2016-01-29",
      "last_synced_at": "2026-11-19T04:16:54.576Z",
      "location_count": 8,
      "location_summary": "Fort Myers, Florida • Lawrenceville, Georgia • Cincinnati, Ohio + 5 more",
      "locations": [
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Lawrenceville",
          "state": "Georgia"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Columbia",
          "state": "South Carolina"
        },
        {
          "city": "Chattanooga",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01027598"
    }
  ]
}